Cargando…
Validation of Cell-Free RNA and Circulating Tumor Cells for Molecular Marker Analysis in Metastatic Prostate Cancer
Since tissue material is often lacking in metastatic prostate cancer (mPCa), there is increasing interest in using liquid biopsies for treatment decision and monitoring therapy responses. The purpose of this study was to validate the usefulness of circulating tumor cells (CTCs) and plasma-derived ce...
Autores principales: | Ladurner, Michael, Wieser, Manuel, Eigentler, Andrea, Seewald, Martin, Dobler, Gabriele, Neuwirt, Hannes, Kafka, Mona, Heidegger, Isabel, Horninger, Wolfgang, Bektic, Jasmin, Klocker, Helmut, Obrist, Peter, Eder, Iris E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391593/ https://www.ncbi.nlm.nih.gov/pubmed/34440208 http://dx.doi.org/10.3390/biomedicines9081004 |
Ejemplares similares
-
Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response
por: Kafka, Mona, et al.
Publicado: (2022) -
Long-Term Treatment with Simvastatin Leads to Reduced Migration Capacity of Prostate Cancer Cells
por: Kafka, Mona, et al.
Publicado: (2022) -
Novel therapeutic approaches for the treatment of castration-resistant prostate cancer()
por: Heidegger, Isabel, et al.
Publicado: (2013) -
Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program
por: Heidegger, Isabel, et al.
Publicado: (2015) -
Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer
por: Kafka, Mona, et al.
Publicado: (2020)